Skip to search formSkip to main contentSkip to account menu

terutroban

Known as: 3-((6-amino-(4-chlorobenzenesulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl)propionic acid 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

NaphthalenesPropionates

Narrower (2)

S 18204S-18886

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Terutroban, a TP‐receptor antagonist, reduces portal pressure in cirrhotic rats
Increased production of vasoconstrictive prostanoids, such as thromboxane A2 (TXA2), contributes to endothelial dysfunction and… 
2011
2011
Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Terutroban is a selective TP receptor antagonist, i.e. a specific antagonist of the… 
2010
2010
Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study
Summary.  Background: Terutroban is a selective prostaglandin endoperoxide (TP) receptor antagonist with antithrombotic… 
Review
2010
Review
2010
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
Platelet inhibitors are the mainstay treatment for patients with vascular diseases. The current ‘gold standard’ antiplatelet… 
2010
2010
Terutroban, a Thromboxane/Prostaglandin Endoperoxide Receptor Antagonist, Increases Survival in Stroke-Prone Rats by Preventing Systemic Inflammation and Endothelial Dysfunction: Comparison with…
This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor antagonist, on… 
Review
2009
Review
2009
New antiplatelet agents: why they are needed.
2009
2009
The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline…
Background: The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a… 
2009
2009
Effect of the Thromboxane Prostaglandin Receptor Antagonist Terutroban on Arterial Thrombogenesis after Repeated Administration in Patients Treated for the Prevention of Ischemic Stroke
Background: The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin… 
Highly Cited
2008
Highly Cited
2008
Hypertension and the absence of EDHF‐mediated responses favour endothelium‐dependent contractions in renal arteries of the rat
Experiments were designed to determine the modulation by nitric oxide (NO) and endothelium‐dependent hyperpolarizations (EDHF… 
2007
2007
Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes
Thromboxane A2 (TxA2) is assumed to contribute to the development of diabetes complications, including nephropathy. We… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)